×
About 733 results

ALLMedicine™ Von Hippel-Lindau Disease Center

Research & Reviews  268 results

Familial Neoplastic Syndromes.
https://doi.org/10.1016/j.ncl.2021.11.012
Neurologic Clinics; Eaton RG, Lonser RR

Apr 26th, 2022 - Familial neoplastic syndromes commonly impact the central and peripheral nervous systems. The most common neoplastic syndromes clinically relevant to neurology and neurologic surgery, include neurofibromatosis type 1, neurofibromatosis type 2, and...

Elongin C (ELOC/TCEB1) associated von Hippel-Lindau disease.
https://doi.org/10.1093/hmg/ddac066
Human Molecular Genetics; Andreou A, Yngvadottir B et. al.

Mar 25th, 2022 - Around 95% of patients with clinical features diagnostic of Von Hippel-Lindau disease (VHL) have a detectable inactivating germline variant in VHL. The VHL protein (pVHL) functions as part of the VCB-CR complex which plays a key role in oxygen sen...

Familial multiple sclerosis in patients with Von Hippel-Lindau disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902760
BMC Neurology; Nath SR, Grewal P et. al.

Mar 10th, 2022 - Multiple sclerosis (MS) is a progressive autoimmune demyelinating disorder. Recent studies suggest that a combination of genetic susceptibility and environmental insult contributes to its pathogenesis. Many candidate genes have been discovered to ...

Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857742
British Journal of Cancer; Maher ER, Adlard J et. al.

Feb 21st, 2022 - Von Hippel-Lindau (VHL) disease is an inherited tumour predisposition syndrome and a paradigm for the importance of early diagnosis and surveillance. However, there is limited information on the "real world" management of VHL disease. A national a...

see more →

Clinicaltrials.gov  4 results

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
https://clinicaltrials.gov/ct2/show/NCT02859441

Nov 1st, 2021 - Objective: Von Hippel-Lindau (VHL) disease is an autosomal dominant heritable disorder in which multiple benign and malignant neoplasms and cysts of specific histopathologies develop in the kidney, adrenal gland, pancreas, brain, spinal cord, eye,...

PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03108066

Apr 13th, 2021 - This open-label Phase 2 study will evaluate the efficacy, safety, PK, and PD of PT2385 in patients with VHL disease who have at least 1 measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). PT2385 will be administered orally an...

Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
https://clinicaltrials.gov/ct2/show/NCT00062166

Nov 14th, 2018 - Background: Patients with the familial cancer syndrome von Hippel-Lindau (VHL) demonstrate manifestations in a variety of organs among them the pancreas. Pancreatic manifestations can range from benign cysts and micro cystic adenomas to neuroendoc...

Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Sur...
https://clinicaltrials.gov/ct2/show/NCT00001668

Mar 4th, 2008 - The von Hippel Lindau (VHL) gene has recently been identified as the genetic defect resulting in a syndrome of multiple neoplasias. Patients with VHL disease develop retinal angiomata, renal cysts and/or carcinomas, CNS hemangioblastomas as well a...

see more →

News  17 results

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Novel Agent May Be Game-Changer in Rare Genetic Disease
https://www.medscape.com/viewarticle/963946

Dec 1st, 2021 - A novel oral agent may represent a game-changer for patients with von Hippel-Lindau (VHL) disease, a rare genetic disorder that increases the risk of renal cell carcinoma and other cancers, a new phase 2 trial suggests. The majority of patients wi...

Dr. Soares on Advances in the Management of Pancreatic NETs
https://www.onclive.com/view/dr-soares-on-advances-in-the-management-of-pancreatic-nets

Oct 20th, 2021 - Heloisa P. Soares, MD, PhD, medical oncologist, assistant professor, Huntsman Cancer Institute, University of Utah, discusses advances in the management of pancreatic neuroendocrine tumors (NETs). In January 2018, the FDA approved Lutetium 177 ...

The Nature of Neuroendocrine Tumors
https://www.onclive.com/view/the-nature-of-neuroendocrine-tumors

Sep 14th, 2021 - Matthew H. Kulke, MD: Neuroendocrine tumors are actually a very broad category of malignancies. We tend to classify them broadly in 2 big groups. One group would be pancreatic neuroendocrine tumors and the other group would be extra-pancreatic neu...

FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease
https://www.medscape.com/viewarticle/956582

Aug 13th, 2021 - The US Food and Drug Administration (FDA) approved belzutifan (Welireg) for adult patients with von Hippel-Lindau disease (VHL) who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancr...

see more →

Patient Education  4 results see all →